Intellia Flags In Vivo CRISPR Knockout Platform As Key Priority For 2023
Executive Summary
After ending 2022 with more than $1bn in cash, the US firm is keen to validate its in vivo approach to gene therapy with investigational new drug applications and pivotal trials lined up for two core rare disease programs.
You may also be interested in...
Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies
Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.
Vera Pins Hopes On Per-Protocol Analysis To Revive Phase II IgAN Asset
The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial of atacicept lifted hopes for the product’s prospects as compared with a key rival candidate.
Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer
The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.